arrow
J

Jan Astermark

Lund University
H指数:48
被引数:8,003

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prospective collection of bleeding rate and factor usage in participants with hemophilia A and B in a noninvestigational product study

在非研究性产品研究中对血友病A和B患者出血率和因子使用情况进行前瞻性收集

2026-08-010
PRE
Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study

利扎珠单抗在无抑制剂的A型或B型血友病患者中的疗效:第3期explorer8研究56周截断结果

2026-06-260
OA
Impact of Fidanacogene Elaparvovec Gene Therapy on Joint Health in Adults With Haemophilia B: Results From a Phase 3 Study

Fidanacogene Elaparvovec基因疗法对血友病B成人患者关节健康的影响:一项3期研究的结果

2025-11-010
PRE
Health-Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab: Results From the Phase IV HemiNorth 2 Study

与健康相关的生活质量、身体活动及关节健康在重度A型血友病患者接受依库珠单抗治疗中的情况:HemiNorth 2 IV期研究结果

2025-09-010
OAAI
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease
2024-12-090
PRE
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia-A Critical Appraisal
2024-12-060
PREAI
Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial
2024-12-011
PRE
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial

Etranacogene dezaparvovec基因治疗血友病B (hope-b): 来自单臂,多中心,3期试验的24个月事后疗效和安全性数据

2024-04-017
PRE
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis

严重血友病A出血结局的匹配校正间接比较: 比较valoctocogenroxaparvovec基因治疗,emicizumab预防和FVIII替代预防

2023-06-224
OA